Navigation Links
Boehringer Ingelheim's Swiss Branch Improves Sales Reporting and Efficiency with MicroStrategy Software
Date:8/26/2009

MCLEAN, Va., Aug. 26 /PRNewswire-FirstCall/ -- MicroStrategy((R)) Incorporated (Nasdaq: MSTR), a leading worldwide provider of business intelligence (BI) software, today announced that Boehringer Ingelheim (Schweiz) GmbH (named here as Boehringer Switzerland) has selected MicroStrategy to improve its sales reporting and efficiency. Boehringer Switzerland is the Swiss branch of the international pharmaceuticals company Boehringer Ingelheim.

Boehringer Switzerland selected MicroStrategy for reporting and analysis of sales productivity data. With MicroStrategy, sales data can now be supplied more rapidly to field sales and management, which helps the company to streamline operations. With MicroStrategy's flexible, user-friendly reports, individual users can create their own reports and work more efficiently. In addition, the reports give Boehringer Switzerland management greater insights into market data to help them plan sales activity and analyze the productivity of regional sales groups.

As part of its extensive selection process, the Boehringer Switzerland management team defined 10 Key Performance Indicators and asked selected BI providers to create several reports with this information. "MicroStrategy made an excellent impression during our evaluation process. In addition, our team in Australia has already deployed MicroStrategy for reporting and has had positive results," said Mr. Gregor Brunner, Department Manager IT of Boehringer Switzerland.

"MicroStrategy provides greater reporting capabilities than other BI suppliers and is very user-friendly," explained Alexander Herter, Business Analyst at Boehringer Switzerland and Project Manager for the evaluation of the new BI solution. "Data can be supplied rapidly and more clearly with MicroStrategy, and the reports serve as a basis for operational and strategic decisions."

"We are pleased to have the Swiss branch of Boehringer Ingelheim, one of the world's leading pharmaceutical companies, as our new customer," said Sanju Bansal, MicroStrategy's COO.

About Boehringer Switzerland

The Boehringer headquarters is in Ingelheim, Germany and the enterprise Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

About MicroStrategy

Founded in 1989, MicroStrategy is a global leader in business intelligence (BI) technology. MicroStrategy provides integrated reporting, analysis, and monitoring software that helps leading organizations worldwide make better business decisions every day. Companies choose MicroStrategy for its advanced technical capabilities, sophisticated analytics, and superior data and user scalability. More information about MicroStrategy (Nasdaq: MSTR) is available at www.microstrategy.com.

MicroStrategy and MicroStrategy Business Intelligence Platform are either trademarks or registered trademarks of MicroStrategy Incorporated in the United States and certain other countries. Other product and company names mentioned herein may be the trademarks of their respective owners.

    Contact:
    Wende Cover
    MicroStrategy Incorporated
    703-770-1646
    wcover@microstrategy.com


'/>"/>
SOURCE MicroStrategy Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
2. AmeriCares and Boehringer Ingelheim Open New, Expanded Free Clinic to Help Families Hit Hardest by Economic Hardship
3. Boehringer Ingelheim Recognized For Diversity And Inclusion Efforts
4. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
5. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
6. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
7. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
8. Do the Swiss Have the Answer to Americas Health Care Dilemma?
9. EMH Swiss Medical Publisher Ltd. Selects Editorial Manager for Online Peer Review
10. Swissray Awarded US Government Contract
11. Swiss Res Employer Stop Loss Product Offers US Companies Cost Savings for Self-Funded Health Insurance Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
(Date:4/28/2017)... ... 28, 2017 , ... NuevaCare, a leading home care agency based in San ... Alto, is proud to announce information upgrades to its blog in the form of ... on topics such as home care (generally) as well as senior care and home ...
(Date:4/27/2017)... ... 2017 , ... The Incentive Research Foundation is pleased to ... a groundbreaking analysis of how behavioral economics can be applied to the incentive, ... programs, the report highlights proven behavioral economics approaches and the powerful role emotions ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. ... at MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron ... approach to helping organizations maximize the benefits of mobility in their operations securely. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: